skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: {sup 18}-F-Fluorodeoxyglucose-Positron Emission Tomography Evaluation of Early Metabolic Response During Radiation Therapy for Cervical Cancer

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2]; ;  [3];  [1]
  1. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO (United States)
  2. Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA (United States)
  3. Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO (United States)

Purpose: To document changes in cervical tumor {sup 18}-F-fluorodeoxyglocose (FDG) uptake during radiation therapy and to correlate those changes with post-treatment tumor response and survival outcome. Methods and Materials: A total of 36 patients with Stage Ib1 to IIIb cervical cancer were enrolled in an institutional protocol examining the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) for brachytherapy treatment planning. As part of this study, FDG-PET or PET/computed tomograpy (CT) images were obtained before, during, and after the completion of radiation therapy. Tumor metabolic responses were assessed qualitatively and semi-quantitatively by measurement of the maximal standardized uptake value (SUV{sub max}). Results: Post-treatment FDG-PET images were obtained for 36 patients in this study. Of the patients, 29 patients had a complete metabolic response on the post-treatment PET, 4 had a partial metabolic response, and 3 had new sites of FDG uptake. Six patients had a complete metabolic response observed during radiation therapy, 26 had a partial metabolic response and 4 had stable or increased tumor metabolic activity. For patients with complete metabolic response during radiation therapy, median time to complete response was 29.5 days (range, 18-43 days). The mean cervical tumor SUV{sub max} decreased from 11.2 (SD, 6.3; range, 2.1-38.0) pretreatment to 2.4 (SD, 2.7; range, 0-8.8) mid treatment, and 0.5 (SD, 1.7; range, 0-8.3) post-treatment. Conclusions: During radiation therapy for cervical cancer, FDG-PET can be used to monitor treatment response. Complete metabolic response during radiation therapy was observed for a subset of patients. Recommendations regarding the optimal timing of FDG-PET during treatment for cervical cancer will require further systematic study.

OSTI ID:
21172512
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 72, Issue 5; Other Information: DOI: 10.1016/j.ijrobp.2008.03.040; PII: S0360-3016(08)00536-1; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Changes in Cervical Cancer FDG Uptake During Chemoradiation and Association With Response
Journal Article · Tue Jan 01 00:00:00 EST 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21172512

Prognostic Significance of Tumor Response as Assessed by Sequential {sup 18}F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography During Concurrent Chemoradiation Therapy for Cervical Cancer
Journal Article · Fri Nov 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21172512

18F-fluorodeoxyglucose Positron Emisson Tomography/Computed Tomography Guided Conformal Brachytherapy for Cervical Cancer
Journal Article · Sat Sep 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21172512